Skip to main
ABSI

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci is a leading AI-powered synthetic biology company with an innovative approach to biologic drug discovery and cell line development, supported by strong preclinical and human ex vivo biopsy data. The company's lead drug candidate, ABS-201, has shown promising results in promoting hair growth and is well-tolerated with a potential dosing regimen of 2-3 injections over a 6-month period, making it a potential best-in-class option in the lucrative hair growth space. With a strong pipeline, high-profile partnerships, and a unique business model supporting downstream revenue potential, we see Absci as a potential >$5B market cap company in the longer-term.

Bears say

Absci is a biotechnology company that specializes in using AI and wet lab technologies to create novel biologics, with their lead product candidate being an anti-prolactin receptor antibody for AGA. While they have increased their projected peak revenue for this product, they will likely require additional funding for their clinical trials and there is no guarantee that their current partnerships will continue to contribute revenues. The potential for success is promising, but the uncertainty surrounding their financing and partnerships may pose a risk for investors.

Absci Corp (ABSI) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Jul 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.84, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.